Trials / Completed
CompletedNCT00467935
Scotoma Reduction in AMD Patients Treated With Ranibizumab
A Phase I/II Study to Evaluate Scotoma Reduction in And Limited Visual Acuity in aGe Related Macular Degeneration Patients Treated With Intravitreal Lucentis
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Retina Research Foundation · Academic / Other
- Sex
- All
- Age
- 50 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
This is a trial aimed at patients with advanced wet macular degeneration and macular scarring treated wiht intravitreal injections of Lucentis.
Detailed description
Patients with severe wet macular degeneration and scarring in the center of the retina may benefit from treatment if the size of the blind spot is reduced wiht injections of Lucentis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | intravitreal injection Lucentis (ranibizumab) | intravitreal injection Lucentis (ranibizumab) |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2007-11-01
- Completion
- 2007-11-01
- First posted
- 2007-05-01
- Last updated
- 2011-07-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00467935. Inclusion in this directory is not an endorsement.